Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.
- DOI
- 10.1093/crocol/otag107
- Published
- 2026 Oct
- Container
- Crohn's & colitis 360
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/crocol/otag107,
title = {Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.},
author = {Long M and Laharie D and Rogler G and Navabi S and Vadhariya A and Eastman WJ and Tian T and Bleakman AP and Armuzzi A},
year = {2026},
journal = {Crohn's \& colitis 360},
doi = {10.1093/crocol/otag107},
url = {https://doi.org/10.1093/crocol/otag107}
}RIS
TY - JOUR TI - Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial. AU - Long M AU - Laharie D AU - Rogler G AU - Navabi S AU - Vadhariya A AU - Eastman WJ AU - Tian T AU - Bleakman AP AU - Armuzzi A PY - 2026 JO - Crohn's & colitis 360 DO - 10.1093/crocol/otag107 UR - https://doi.org/10.1093/crocol/otag107 ER -
APA
M, L., D, L., G, R., S, N., A, V., WJ, E., T, T., AP, B., & A, A. (2026). Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.. Crohn's & colitis 360. https://doi.org/10.1093/crocol/otag107
Source records
- pubmed · retrieved 2026-11-10T14:38:47.799Z